Aastrom seeks to raise $12.5 million in stock and warrants exercise:
This article was originally published in Clinica
Aastrom Biosciences (Ann Arbor, Michigan) yesterday announced a common stock placement worth around $9.1m. 8 million shares are being placed with institutional investors at $1.14 per share. The company will also issue warrants that could generate a further $3.4m in revenues. Aastrom and its wholly-owned subsidiary Zellera are optimistic that a second bone-graft trial announced last week will demonstrate the effectiveness of the group's tibial repair technology.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.